SB 180 is a comprehensive rewrite of Delaware’s pharmacy law in Title 24, Chapter 25. It modernizes definitions, reorganizes the Board of Pharmacy’s authority, and updates licensure, permit, discipline, inspection, and recordkeeping provisions for pharmacists, interns, pharmacies, nonresident pharmacies, manufacturers, wholesalers, outsourcing facilities, and medical gas distributors. The bill also clarifies the Board’s objectives, composition, meeting procedures, and enforcement powers, while aligning terminology with current pharmacy practice and federal concepts such as biological products, outsourcing facilities, and the FDA Orange Book.
The bill expands and clarifies the scope of pharmacy practice in Delaware. It expressly authorizes pharmacists, under statewide protocols or collaborative arrangements, to order, test, screen, and treat certain conditions such as influenza, strep throat, COVID-19 and other respiratory illnesses, lice, skin conditions, and other public health threats. It also authorizes pharmacists to initiate, dispense, and administer HIV pre-exposure prophylaxis and post-exposure prophylaxis, administer immunizations, dispense contraceptives, and perform certain waived laboratory tests. The bill updates substitution rules for generic drugs and biological products, emergency refills of noncontrolled drugs, prescription labeling, and patient counseling requirements, and it adds an emergency exemption allowing out-of-state pharmacists to provide services during declared disasters.
The bill’s impact on state law is substantial because it replaces older permit-based language with a more modern licensing framework and increases the Board’s enforcement and administrative authority. It raises or revises penalties for disciplinary violations, expands grounds for discipline, requires more detailed background checks and continuing education, and strengthens rules for pharmacy records, inspections, and nonresident pharmacy oversight. It also creates or updates licensing standards for pharmaceutical establishments and key personnel, including manufacturers, wholesale distributors, outsourcing facilities, and medical gas distributors, and it requires compliance with federal supply-chain and compounding standards.
The overall sentiment reflected in the vote history is strongly supportive and noncontroversial. The bill passed the Senate 20-0 and the House 40-0, indicating unanimous approval in both chambers. No committee transcript excerpts were provided, and there is no recorded opposition in the materials supplied.
The main points of contention that could arise from the bill’s text involve the expanded authority of pharmacists, the increased regulatory burden on pharmacies and nonresident pharmacies, and the higher monetary penalties for violations. Potential concerns also include the Board’s broader discretion over licensure, discipline, and emergency practice exemptions, as well as the operational requirements tied to testing, HIV prophylaxis, recordkeeping, and reporting to DelVAX. However, based on the available voting record, these issues did not produce visible legislative opposition.
SB 180 amends Delaware’s pharmacy statutes in Title 24 by replacing and updating numerous provisions governing the Board of Pharmacy, pharmacist licensure, pharmacy permits, nonresident pharmacies, pharmaceutical establishments, discipline, and enforcement. It broadens the legal scope of pharmacy practice, authorizes new pharmacist services under protocol, and updates substitution, labeling, and emergency refill rules. It also increases penalties and strengthens compliance, inspection, and reporting requirements for pharmacies and related entities, while adding an emergency-services exemption for out-of-state pharmacists during disasters.
The most likely areas of contention are the bill’s expansion of pharmacist authority into testing, treatment, HIV prophylaxis, and immunizations; the increased regulatory and reporting obligations on pharmacies and nonresident pharmacies; and the substantially higher administrative penalties for violations. Stakeholders such as pharmacists, pharmacy owners, nonresident pharmacy operators, and manufacturers could view these provisions as either necessary modernization or as added compliance costs and oversight. The bill also gives the Board of Pharmacy broader discretion over licensure, discipline, and emergency practice exemptions, which could raise concerns about administrative burden and enforcement reach, though those concerns are not reflected in the unanimous votes.